Important links:

Jaguar Press Release (7/9/24): https://jaguargenetherapy.com/press-release/jaguar-gene-therapy-to-initiate-inaugural-pediatric-clinical-trial-targeting-a-genetic-form-of-autism-spectrum-disorder-and-phelan-mcdermid-syndrome/

Letter from Jaguar to the community (FAQs):  https://drive.google.com/file/d/1y03qTiDfzG66BNezJRGih3ogvaPYXCRu/view?usp=sharing

Registration for Jaguar 7/11/24 webinar:  https://events.teams.microsoft.com/event/924cd1a7-22aa-448c-a9d7-662ad6ae8250@ef5e8ff3-9734-423d-9836-a5011bdae2ea

Dear families,

Jaguar Gene Therapy has received agreement from the U.S. Food and Drug Administration (FDA) to administer JAG201, a gene therapy for Phelan-McDermid syndrome (PMS) and a genetic form of autism spectrum disorder (ASD), to both pediatric and adult patients as part of the initial clinical trial. 

With this clearance, Jaguar will proceed with dosing pediatric patients (2+ years) with JAG201 and expand into adults (18+ years) following the pediatric cohort.

For more information, check out the links above for the press release, a letter from Jaguar to the community with FAQs, and a link to an upcoming webinar where Jaguar will present and take questions.

Kate Still, Ph.D.

PMSF Scientific Director